Takeda Pharmaceutical Company has announced breakthrough results from Phase 3 trials of zasocitinib (TAK-279), an innovative oral treatment for moderate-to-severe plaque psoriasis that offers patients a promising new option for…
Menopause-related insomnia affects approximately one in four women during the menopausal transition, yet it remains significantly underdiagnosed and undertreated. A new analysis published in Maturitas journal and reported by The…
FibroBiologics Inc, a clinical-stage biotechnology company, has announced a significant breakthrough in regenerative medicine by submitting a Phase 1/2 Investigational New Drug (IND) application to the US Food and Drug…
Altimmune has released updated 48-week results from its phase 2 trial of pemvidutide, a GLP-1/glucagon dual receptor agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), demonstrating continued weight loss and…
A new oral medication has demonstrated remarkable effectiveness in treating hereditary angioedema (HAE) attacks, offering patients significantly faster symptom relief compared to existing options. According to Healio.com, the RAPIDe-3 study…
Gilead Sciences announced positive topline results from the Phase 3 ARTISTRY-2 trial on December 15, 2025 and reported by Drugs.com, marking a significant advancement in HIV treatment options. The trial…
The biotech sector witnessed significant momentum as four clinical-stage companies announced compelling data across muscular dystrophy, immunology, and obesity treatment areas, triggering substantial stock market gains and investor enthusiasm for…
Genentech announced landmark clinical trial results demonstrating that giredestrant, an investigational selective estrogen receptor degrader (SERD), significantly outperforms standard endocrine therapy in treating early-stage ER-positive breast cancer. As reported by…
A groundbreaking achievement in genetic medicine has emerged as the European Medicines Agency (EMA) recommended approval of Waskyra (etuvetidigene autotemcel), the first gene therapy specifically designed to treat Wiskott-Aldrich syndrome…
The developer of the Promega OncoMate MSI Dx Analysis System recently announced the FDA’s approval of the system identifying patients who may benefit from the combination of Lenvatinib (Lenvima) and…
Tonix Pharmaceuticals announced plans to initiate Phase 2 clinical trials in 2026 for TNX-2900, an innovative intranasal oxytocin formulation designed to treat Prader-Willi Syndrome (PWS), a rare genetic disorder characterized…
Aldeyra Therapeutics, Inc., a biotechnology leader in immune-mediated disease therapies, has announced encouraging results from its Phase 2 clinical trial evaluating ADX-629 in patients with alcohol-associated hepatitis, and is now…
BridgeBio Pharma has reported decisive success in a pivotal phase 3 trial for its rare disease drug BBP-418, aimed at treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Reported by Fierce…
Merck & Co has taken a significant step forward in its immunology pipeline by initiating Phase IIb clinical studies for tulisokibart (MK-7240), its investigational therapy targeting immune-mediated inflammatory diseases. According…
Merck has announced a significant expansion of its clinical development program for tulisokibart (MK-7240), an investigational monoclonal antibody targeting the inflammatory mediator TL1A. Reported by Drugs.com, in October 2025, the…
Immuneering’s midstage pancreatic deep cyclic MEK protein inhibitor, (DCI), almost doubled the standard overall survival. It is a deep cycle inhibitor that targets key pathways in a pulsed manner. Results…
Editor's Note: Patient Worthy is proud to share this article from our friends at the TESS Research Foundation. To see the article in its original format, please click here. TL;DR:…
Lancet Oncology Recently published reports updating the findings from the phase 3 DREAMM 7 trial involving 494 patients averaging ages 64.5 years with the median follow-up of 39.4 months. Accordingly, patients…
Calidi Biotherapeutics has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Fast Track designation to its experimental therapy, CLD-201 SuperNova, for the treatment of glioblastoma.…
Microbiotica, a UK-based biotechnology company focused on developing microbiome-based therapeutics, has reached a significant milestone by completing patient recruitment for its phase 1b clinical trial in ulcerative colitis (UC). According…
A new potential treatment for light chain amyloidosis is making significant strides in clinical development. According to a recent update reported by Drugs.com, the phase III clinical program called “CARES”…
A significant milestone has been achieved in the fight against blood cancers, as the first patient has been dosed in a pivotal Phase 3 clinical trial evaluating a promising new…
Researchers at the University of California, Davis, have developed an investigational brain-computer interface (BCI) that holds promise for restoring the voices of people who have lost the ability to speak…
HepaRegeniX GmbH has announced the dosing of the first patient in its Phase Ib clinical trial of HRX-215, a novel small-molecule inhibitor designed to promote liver regeneration. This marks a…
Applied Therapeutics has encountered a significant setback in its quest to bring a new treatment to patients with a rare metabolic disorder. According to Biospace.com, the company announced that its…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
